In the EHC, high SLC2A1 expression was significantly associated with advanced T stage, advanced N stage, large tumor size, diffuse type, high histological grade, lymphatic invasion, high PD-L1 expression, low PNI, and chemoresistance, compared with low SLC2A1 expression (p = 0.001, 0.001, 0.003, 0.002, 0.001, 0.001, 0.028, 0.048 and 0.002, respectively) (Tables 1 and S1). This evidence concerns the gene SLC2A1 and neoplasm.